Literature DB >> 21394642

Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb.

Nicholas L M Cruden1, Ninian N Lang, Thomas J MacGillivray, Neal G Uren, Keith A A Fox, David E Newby.   

Abstract

Upregulation of vascular B(1) kinin receptor expression has been reported in human atheroma, but its role remains unclear. We examined vasomotor and fibrinolytic responses to selective B(1) and B(2) kinin receptor agonism in the human femoral circulation and correlated responses with femoral arterial plaque load. Femoral arterial cross-sectional area, blood flow and plaque volume were determined using intravascular ultrasound and Doppler during selective arterial infusion of Lys-des-Arg(9)-bradykinin (B(1) agonist), bradykinin (B(2) agonist) and sodium nitroprusside in eleven patients undergoing diagnostic coronary angiography. Net release of tissue plasminogen activator was determined across the femoral vascular bed. Mean femoral arterial plaque load was 8.1 (±0.9) mm(3)/mm of vessel. Bradykinin and sodium nitroprusside caused dose-dependent increases in femoral blood flow (p < 0.05 and p < 0.005, respectively). Bradykinin caused a dose-dependent increase in net tissue plasminogen activator release (p < 0.05), which was augmented by angiotensin-converting enzyme inhibition (p < 0.05). There were no correlations between plaque load and bradykinin-mediated vasodilation or tissue plasminogen activator release. Lys-des-Arg(9)-bradykinin had no effect on blood flow or tissue plasminogen activator release. The vasomotor and fibrinolytic actions of bradykinin in the femoral circulation are mediated solely by the B(2) kinin receptor, irrespective of the presence of atheroma. In keeping with previous data, bradykinin-mediated tissue plasminogen activator release was augmented in the presence of angiotensin-converting enzyme inhibition consistent with its putative vascular protective effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21394642     DOI: 10.1007/s00380-011-0124-6

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  30 in total

1.  Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity.

Authors:  J W Doucette; P D Corl; H M Payne; A E Flynn; M Goto; M Nassi; J Segal
Journal:  Circulation       Date:  1992-05       Impact factor: 29.690

2.  Heterogeneous limb vascular responsiveness to shear stimuli during dynamic exercise in humans.

Authors:  D Walter Wray; Abhimanyu Uberoi; Lesley Lawrenson; Russell S Richardson
Journal:  J Appl Physiol (1985)       Date:  2005-02-17

Review 3.  The B1 receptors for kinins.

Authors:  F Marceau; J F Hess; D R Bachvarov
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

4.  Endotoxin sensitization to kinin B(1) receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects.

Authors:  D deBlois; R A Horlick
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment.

Authors:  Maria E Marin-Castaño; Joost P Schanstra; Eric Neau; Françoise Praddaude; Christiane Pecher; Jean-Louis Ader; Jean-Pierre Girolami; Jean-Loup Bascands
Journal:  Circulation       Date:  2002-02-05       Impact factor: 29.690

6.  Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.

Authors:  C Labinjoh; D E Newby; M P Pellegrini; N R Johnston; N A Boon; D J Webb
Journal:  J Am Coll Cardiol       Date:  2001-11-01       Impact factor: 24.094

7.  Endothelium-dependent relaxation to the B1 kinin receptor agonist des-Arg9-bradykinin in human coronary arteries.

Authors:  G R Drummond; T M Cocks
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

8.  Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy.

Authors:  Fraser N Witherow; Pamela Dawson; Christopher A Ludlam; Keith A A Fox; David E Newby
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

9.  Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.

Authors:  Nicholas L M Cruden; Fraser N Witherow; David J Webb; Keith A A Fox; David E Newby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-04-22       Impact factor: 8.311

10.  Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist.

Authors:  J R Cockcroft; P J Chowienczyk; S E Brett; N Bender; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

View more
  2 in total

1.  Expression of the genes encoding kinin receptors are increased in human carotid atherosclerotic plaques.

Authors:  Yapei Guo; Tiantian Liu; Xueyuan Li; Min Zhang; Lei Shi; Hengfang Liu
Journal:  Biomed Rep       Date:  2015-01-29

Review 2.  Function and structure of bradykinin receptor 2 for drug discovery.

Authors:  Jin-Kang Shen; Hai-Tao Zhang
Journal:  Acta Pharmacol Sin       Date:  2022-09-08       Impact factor: 7.169

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.